{"ticker": {"uuid": "1a591078-2b4b-4c42-9ccb-8d5fba81165f", "symbol": "GMAB", "name": "Genmab A/S", "exchange": "CPH", "country": "DK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Genmab stock trades mixed as investors weigh Darzalex growth and upcoming earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOUTZzR2Q1WGFEb3BIQ0E0WVdhWHNfejRubmhnY0czZWd4cWdrYVo4NnJVUEF1YTRmdkJnWndlTnU0ckJHUDhnTmxLUlNTTnpUNUJCZUE0UGViZjk1X2pHVUhLaXBhRTBNNS13cjBvbW1XNXE4ZFVkeHdFakUzRWJLVFlxSFhrcmhSeVJCNTRreVZDR21lRG1Fb3U3c2ZCbEpuV0UyQTVSNmdFOGYwTDZNLVR3OGp4WDJPUG52WktQWnBvQzR3Y2hOYXpDY2s?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-18T13:30:57+00:00", "published_display": "18 Jul 2026 13:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (Nasdaq: GMAB) reports USD 4,207 million Q2 DARZALEX sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcFVqSWZyYktvYkotSVo1TnBtUG94X2FiNTFhYzBMMGU4MDFGanpKT2N2VEp0ZnVKRDBnUmUzMUxFZ2ZzRy1SaFR4UzJlOWxxQk5yZ1lncENXWDQ2N1ludG1QLVJ5MXhMYVN2MktjOHhocmxhRmt1c0Jja00wbkpLZF9PbUtrSlMwSEFibG5EOWpia2RlZXN4d3dfWTJ3TGNnMDFqMjk5UGtSQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:22:42+00:00", "published_display": "15 Jul 2026 11:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab stock reflects biotech growth focus for long-term investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbmZrYzBzdENGdk02NDZ1Tll0OVl4U3JRV2xUUFo5V2hoNUtwQkRtZzBvbE5BUUI3M29PVktEY0hiTEh5M2tSWWF6dElMRDJQcTg1aENxTm1uSndtNlJtMVlyWkRwdEdYZzlVVHYtQzNPdVBhd0VaNzlkM3E5ZzJqamozN3ZfSEUwOFpCSEhiUU9hd09SaFYzZVlleXZRMk5qMXpORnotSjFpNV9kSHJTNmpqdkgyNnA2cmFzUWs1bFExM3c?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-14T05:13:18+00:00", "published_display": "14 Jul 2026 05:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) Stock Analysis: Unlocking A 26.68% Upside With Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNT3JiNVJ4X3lyYnlIVXNFWUZ5MVBQb0g5cGtKbGZzWjN4NlBkN3VRa0hnb1B3UVdTV2NHSGZKcVJaaVBRM2NFRFpXdXU4QzdZeGZMQ3dsRzUyalBNTjFTRUxBa3ZGVFl4VzRtNUs3UUVESzdMOTZTNzBQaDc5VlhnVDRkRHhjazFTR2xfX1F6eEdDcld3ZUJHaE5rQXZ1RWk2TnJCeXpmc3Z5V3VTY0MxZmY3SlpiRnc1OU1ZRjFTa2R3c09MdjZBNQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:19:12+00:00", "published_display": "13 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab stock reflects the biotech group's global oncology ambitions", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNVEFSS0xsNktoM0tnY2E5U2VJTHN6UFo2Njh2NGRCWkhDbDVyNFhjd0w5clZvZ2ZGenVZZHNQMXlZLWtvbTA3dWkxNkRaYjhsNmxFamdoVFlGaHJwa202OVFIZEJMaENJa0RzWS1FUHdsZlhKSGdKR2paTFdvdFppRXVJMlRDckxHWHBPZVNiZmJLQnZvSjZKcUJtTFpYb05oV2dJRzlSOVhEdDFxWWNfVGQ1Q2E4ZEV4cVBPcmh3TjMya05H?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-12T07:02:01+00:00", "published_display": "12 Jul 2026 07:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNFpiZWVhZ0ZDNnlrS1lKcGl5R3hGMDNMMFBHcGY4UEJTd0tQUWpBTUhJN2J5V3M3MG5zaGR1LVJxQTU3a2JuclpJc0NvOGJIbmVsNEgydlVRLVhmcGE0dHFnQmkzWldrZVp1U3FWZmJEeHg2QlpfZm1mM3RyVWU4T212TmdWblliR2lkVHQzSzBJQURySzc1NldEZ05PckxK?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Europe approves Genmab's TEPKINLY combo for relapsed follicular lymphoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNQnU3NnNXVm9lM3FhOFF2MUNidnZKaEZQeFBLWUZIQXRvWFp2YnJUNDNMaDgzSDJPb1ljWWw3UDd1a0xjQko4TnRITkNfZTI3dHZ6N2gybGs2SUJIdzFZZ1N4UkN1SlI2Z2JVQVBmd3N4dklJcFdoVEdxWVd6Tms0LUtlRURFY0ZyVTJnM2JuNTRqYklOQS1mYURLUnViV042S202SlBHQkZJRzJnWTd0TEpn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab lymphoma trial cuts progression risk 60% in phase 3 study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNckZUcExPdF92eDZNTC1FamFmaUhwUUFiYTE0OGVxN1FoVFFUMHo4ZEJGS05ZNzFDaTB5RkxnT05lZVplV3BjVWtKVDdHZ3kyMEVNdjJVWWVSSVFhellVR19xRy1TZkd4Q0Q2aktLMThLRGpEYUtjdjdkYkhhUTR4WTRqSTBSempudWxiaWVpbGgzY3BUb3hCYXJ3VE92Ym9ZcDRqWmdQZll1SUhralprczkzeGwwVi1w?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capital Increase in Genmab as a Result of Employee Warrant Exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOZjBhOW9qWTEzaUtGdVotcGZlUDRtVld5QzRFQXFNWHBWZVpUZnh4Q2Y5V3U2U1JEUE5lbjFoa1FRWnJiT3JyWU9qWEVXRzBmUV9qY2kxX21sT3VSY1RKVnEzS2ZablpfODJfN252eGVteFlqQXN1TFRhZlFuNFBpX2s3N2VXYlBpOWNZOVlST2t4QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (NASDAQ: GMAB) issues 185 new shares from employee warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQcFd2MVlaM2k1S0NWcFhRSTBLb2ZLZTdZSVB4bjRIUjVvT3VJUUc0MHpyZGZfRGgyYzRjZmFQMEl4ZTlET3pYM3ZBcXRHT0R1cTJYeDBWX3VkTUZ4Y21IblBFZE5kMlc4NWxsOFRrQ25DVXQ4U282TmF4YldiLUVUVzRQTWRnN3pORldpeXhCTFZ0VXBlWXJnWG1PRFcwOTY1YTNXTEh6SVRiQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Orbis reduces Genmab (GMAB) stake to 4.99% of voting rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUG0yUTFYNVpEcG1lNXFSM1BpTzRjQml3aFhZWktNRDRIemozZ3VWTG1US2luX0dXNXd6Szd3a1E5ZTRoVExoVUtuWHAtenJNSmZHekR4U3E1RTgwb2h3Q3pnYk85Wkx2YzZUR2lJNDBVNWlweWZoblhzQ1gwRTdRLU1WdDV6Qkd5M2pKb0JKT291dExDR2FxNFNMdkN5cUVsdEtDUXlJTVNQZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grant of Restricted Stock Units and Warrants to Employees in Genmab", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOcGl1U3JPOFZkcGxYX2d6dFNlNW1sNmlKUWpjLXhvMDlvdV92N2Q0WTBrbDg3ZUZvZXFNdjB6bHVvbkZ6a0N3V3N0ZEFNc0x6QlJsTVVZdWxoOGFjR0l5Rzl6d2FuX1RkWHlvcDVUbVU1bmNNWHlTRTJJRDdZNUZKTEV5LVMyLTF6RHpYN043LXRBTllRS3pvME9NR3ZqME9IRTFZN0lnSUVIcHU4Q1JzYWpyOWZuOFhCaUJYazZ2S3RLQlNnWkhaMy1XVnptYVhnbEdzYWFB?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Assigns Buy Rating to Genmab (GMAB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNM1VNTnRZb3pWZjUya0VoS2RBdWs1X2VORTgxWlRDTkh1QTdxQWhGOThweHhIaE1lcEdUanFhb3YtbXdnb1ZHLW5ObHQ0bUVUYjZzWnV6VDdNR0x4VWE5VUhQdi1EbF9jZEtuSXFLWHhhS0dOUkpJemlXTE9naFYyWVpRXzBESXNuRE8tcE5uUUR3VlI2d0RQUEhaUWZ6Zw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/ S stock (DK0010272202): board share sale keeps focus on Denmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOdU1KVmlpUUoxUXpPVFQyY2NCMW9rYXEwOHNhMW5hWkF6UDgzbGpVaGdkakdvYkxBNnZXZ1FIdW1QMkpEcEI4ZVVPOHpKd1R2OVpQT0RFTmZUVjBtQUQtOGVqN1QwODUyenhnN1N2RUZCNXdrNm11OGtyczByUTBESEJwcmJDWjJ3TXEwNlZZYTFmLTlzeDR5UHgwUG5iUVl1Rm5XSnp4a0xtc0Nka2lFVGZkVnFoRmtJWC1STk5aX0c3bUNrS0ZB?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab\u2019s epcoritamab phase 3 lymphoma results set for ASCO and EHA 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSEdhWGhwYXZIaDRubmctcF9WdTNQX3FfMjlULWJySy1ZLW9VWVNYX0JsWkRLdm5LUHlROGZ5U3llRktocVhPZ2tKbHpLal9rNFBaZFhHTEh2c29qVXNXX2RsaUIzNkw2R0pydkFGcWxZS1NMZndYOFVuQ2dNX085Y1VKbi1reG9ySEVISGJzMXo2TVVNQTZmMVh0UFZrcXVMQUdNNERVYnF1NE1uUUJCSHhCUUE3WVdBVUFGTw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNLWV6MExvM1NSUEJ5eE5CaU1tZERrby1IaFFnN2IxR2xpWFo0NjVZczY1VUkyT3g4NWI5TU8tMm5iaGVQdU90eEVmMXhoRzhzQnBBd3hSTUdHaTJRSFo3REJHLUpLWjRPSVRPYVNlOFl5SGc5d0VCM1Q2b3JmZ29DOGFla0RManlPdFR4bEVLRnAxbEljNThRdU90aDczdw?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/ S stock (DK0010272202): Shares up 3.48% on employee warrant exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQWHpHWFhUSE85dnVFcTQ3dF9BMjJYbXk5VlhUNm9rZ084YXYzVmdiNk1rLS1ZeHUySFVLbWd1dGZZMXVpd09FV1NabnhnN3hTYk14U0tITXFPak4ycHc1eWkxekhFS2RBQXZmTjhGWFNLTTRidUxqeU9lSjlNODFvektmbDZNUDRxeGZidmNac0FXaXBUV3Bwa1BzN0xuZ3g1WXRVSERINTdwMnJUN0lLeGZNcTBvNWtlamUzRUdQZE8?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi\u2011Year Share Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOUjhiOXlYYkF3RHFBUXVPY2tTbzQ4VlJCandIeDhHMmJrZzl5YWIyVDA2UmRXTTFSLWFlMnNrRnFlcHROUVdZUnVsVHBaSTljOEphVFM2bkhtZWJTbk1fekc2OWVYZnRZLU9VZ3FFT1ZrOVhsNlZxdzFrei1HTWxtdk1lazVfN0xzY0x1Z2ZidWFaNkk4UUdUYUlhNA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNaUh6a2RmMnNjNFB2VnI3MTNTTGlfWTl6WExfRFhzRHRJOHJhdzhYbkNld0NaLUFpekFfemdPbmdSM1pCaG5hcEZTaGQ2WEhZWGJqSXZReWh0djNMZDlrUjZQSWZVbHJaRERwQ0dpRkFBclBZZ29HT1Fvc2VueFFvMG8wR2hMUEZKeDIzZlVaWEhpQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Rated Outperform on Oncology Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZmpxd1NpbTVHX3pZc2VyVjVpWVliSUNWYmFLbmZObkk2ejdmc0k1ME9ZdEwwZjFhVkNIblYyMTJBdWF5NlZfeVVueldkbU9Ydi1EUERPYnVsVUp0cm0wRmZqcXdwOXpZV2tyVXFndWppZHg4a21GN0JQQW9RNzVlUnJpMndkZHJreXNOUEFxZ2VCaHE1ZkhMTDJFT083X1FDMjdneDVvRnBRZw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Genmab\u2019s (CPSE:GMAB) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQOXhrV3ZBMURTTVVITTdQZ1Z3YzYxUE40alV4bEJ1VjN4N19rbTdmdkN1NWVWdThHeXFiOE5WNnotWEFVcE1GVTBIS1dOdzZPNVFWdUxmLUdqM3VCbHdWa09hWGJ5R0JUek9OQnRDZFBISnNfU3NrblpYTGtuTGZKcFFtcXpKaldOT1VMbE9aNHR0WnI3WmVxYjhWd1g?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQk9kRTlPdmQtaF9uUVhlTXhHSjIxd1JJZ2toUEJTUXQ0c3k4N3dqNlNva0VvREJYYWVwaHVNQTBHUm5zbVd6MGZ6OHQya1JPRk5QZ0JvUnhGU21OR1hZNmxQR0FOTDRPTElWUnZ3aThqYXhBdU1aa1ZodVgxWGhMTDRoemtoeFd6TFdnd2hLUi1nN2FFUlpBSkg1ZFVzNVJl?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNdnJwT19rRjVEN3JfUnBWTlJ1bUZZUG1tRWJBX21KYWtDcmJWWkw5MnVOaWgwR0JKeXQwUkU4cU9yOG54R0NiMnoxc1czbjV6eXZyOVV5eHMxb1dtbjExbmUtNXp1UHFocVUwZjFrRHhHYlVDb2xfd3ZNYnVIbGlVczM5aFh6bF82WmJ5eWlpVHdqWHJfa3Z1Vnp2ZDRmRHBaM2RQZ1NNOWRRUzE5QWh3SW8zcFExUDZvRkVKZVRSdVBsZw?oc=5", "source_name": "ChartMill", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNOTZnQTlGYnljWm1NT25BN2tRQVl4dzNqZWIyZU5mOG04MHE1WWJCZTVad2RIaFdXS3l6QUJuTTg0ZjBNWjh0SUNfeU1ZTUtubWtyYWZFZnozWWZjZWxDaWtmQXNYYXdoVWt3UjhIbURYM19CS21FUkZLUl95Tmt1TlljR0dpLW5S?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNcm5lb2IwQUhyVEFlYmFRaG40U0lzUzdOVU5HVzd3ZDFiQk96RHdLWUxVTXcwUGt0MUhCZkloUjQ4akwwUG5WMzZZSGN2N252ajZyMmgyTGp0OExvYlZJby1UQUtFSlhYRUVkQ210YmZkNE8yVXBnQ0RVYnRFMXhMT09R?oc=5", "source_name": "Market source", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB)\u2019s Future Potential Underappreciated by Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOWWlrWWpHU1pOaVU2TlAzaUhtQ19uc3kzU0htYzJyYUJGeTJCRlI3RHRqT21VYzUzYVYxVGhvQVFaWDhtVmtzQktDVUNCS3pjUGxYeFBfbkU4eG1zRnd2X1RKRVhmbTREeFI5NTZ2azFvdW92LTE2dmt1WUpOV3NDRWlNc2M1bWhFYUpwcndmWVhGeWxWOFE?oc=5", "source_name": "Market source", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwJBVV95cUxOSUxlQzR6YUpRV2tWV193V0RHRURoeFNBWjVTWVBmZXduWkpOQ1Z6bGlYX3NlTjB0WEo4eGNWV21jNE9lNlBwc1g0LWRsWTViaEhGUlpzSGh2ZUdnWW5ld1kzSHhQUThPWV9VX1VQekppQ2dBMjNTV3ZlMTBORUR3a1VkUlFhWFhXQ1FEd2JHQ2Y0ZmZfSjJpTjB5endJLVY5czlNQzJwMzY2bkh6VjdmMEFfMTZLTkFFVjFrRnFpckF6TGtESTFiR2hlckpWcTN0VVFyU0RqNUZFNkt2cW9SZkZnWThXN0VsVDhNbmtFVE45YlZJVy1feE52Mk9NUkNLUWZVOFB5ZGZLX25vb3FjWG9VTkdOZktRVjZj?oc=5", "source_name": "Business Wire", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG-Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwJBVV95cUxNbk1fdm9zcGZ4WGRoWW5oLWdpTmV1QkJzdkR2cmtNWm1yamRrM1dUZHExMWJDbGRNTEVES0ZsY1VTbGdmZUkwS0lyOWhkY29XMER0LXBKQmtxaTBVc3BlY1Z4NV9jc05TR1E1Y3QyaUxadjlJdHhfdGNHYkswRFd0ckcyU0xLazVFVXE0M3J4c0kwRl9EemRrSlFfU2VDQk9PTHNrakp3LWtLckdiLUNOYmpqbjFJUDhpTHQ4STFaR3g1OGl1Nm1mZ21RWDFORlY4QThrckJVZWM3dmpTendXaE5fcjRVeE9tcFZZaER5ZFJDYmdPNjRPRnd6THZldUhINlpFRk9QaXNrdEpIR1BRZTlLSXZOUnVFMUFTbnhnTFc5N09YUHFXWGZZUTlCVkU?oc=5", "source_name": "TradingView", "published_at": "2025-04-01T07:00:00+00:00", "published_display": "01 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Genmab stock trades mixed as investors weigh Darzalex growth and upcoming earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOUTZzR2Q1WGFEb3BIQ0E0WVdhWHNfejRubmhnY0czZWd4cWdrYVo4NnJVUEF1YTRmdkJnWndlTnU0ckJHUDhnTmxLUlNTTnpUNUJCZUE0UGViZjk1X2pHVUhLaXBhRTBNNS13cjBvbW1XNXE4ZFVkeHdFakUzRWJLVFlxSFhrcmhSeVJCNTRreVZDR21lRG1Fb3U3c2ZCbEpuV0UyQTVSNmdFOGYwTDZNLVR3OGp4WDJPUG52WktQWnBvQzR3Y2hOYXpDY2s?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-18T13:30:57+00:00", "published_display": "18 Jul 2026 13:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (Nasdaq: GMAB) reports USD 4,207 million Q2 DARZALEX sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcFVqSWZyYktvYkotSVo1TnBtUG94X2FiNTFhYzBMMGU4MDFGanpKT2N2VEp0ZnVKRDBnUmUzMUxFZ2ZzRy1SaFR4UzJlOWxxQk5yZ1lncENXWDQ2N1ludG1QLVJ5MXhMYVN2MktjOHhocmxhRmt1c0Jja00wbkpLZF9PbUtrSlMwSEFibG5EOWpia2RlZXN4d3dfWTJ3TGNnMDFqMjk5UGtSQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:22:42+00:00", "published_display": "15 Jul 2026 11:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab stock reflects biotech growth focus for long-term investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbmZrYzBzdENGdk02NDZ1Tll0OVl4U3JRV2xUUFo5V2hoNUtwQkRtZzBvbE5BUUI3M29PVktEY0hiTEh5M2tSWWF6dElMRDJQcTg1aENxTm1uSndtNlJtMVlyWkRwdEdYZzlVVHYtQzNPdVBhd0VaNzlkM3E5ZzJqamozN3ZfSEUwOFpCSEhiUU9hd09SaFYzZVlleXZRMk5qMXpORnotSjFpNV9kSHJTNmpqdkgyNnA2cmFzUWs1bFExM3c?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-14T05:13:18+00:00", "published_display": "14 Jul 2026 05:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) Stock Analysis: Unlocking A 26.68% Upside With Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNT3JiNVJ4X3lyYnlIVXNFWUZ5MVBQb0g5cGtKbGZzWjN4NlBkN3VRa0hnb1B3UVdTV2NHSGZKcVJaaVBRM2NFRFpXdXU4QzdZeGZMQ3dsRzUyalBNTjFTRUxBa3ZGVFl4VzRtNUs3UUVESzdMOTZTNzBQaDc5VlhnVDRkRHhjazFTR2xfX1F6eEdDcld3ZUJHaE5rQXZ1RWk2TnJCeXpmc3Z5V3VTY0MxZmY3SlpiRnc1OU1ZRjFTa2R3c09MdjZBNQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:19:12+00:00", "published_display": "13 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab stock reflects the biotech group's global oncology ambitions", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNVEFSS0xsNktoM0tnY2E5U2VJTHN6UFo2Njh2NGRCWkhDbDVyNFhjd0w5clZvZ2ZGenVZZHNQMXlZLWtvbTA3dWkxNkRaYjhsNmxFamdoVFlGaHJwa202OVFIZEJMaENJa0RzWS1FUHdsZlhKSGdKR2paTFdvdFppRXVJMlRDckxHWHBPZVNiZmJLQnZvSjZKcUJtTFpYb05oV2dJRzlSOVhEdDFxWWNfVGQ1Q2E4ZEV4cVBPcmh3TjMya05H?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-12T07:02:01+00:00", "published_display": "12 Jul 2026 07:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNFpiZWVhZ0ZDNnlrS1lKcGl5R3hGMDNMMFBHcGY4UEJTd0tQUWpBTUhJN2J5V3M3MG5zaGR1LVJxQTU3a2JuclpJc0NvOGJIbmVsNEgydlVRLVhmcGE0dHFnQmkzWldrZVp1U3FWZmJEeHg2QlpfZm1mM3RyVWU4T212TmdWblliR2lkVHQzSzBJQURySzc1NldEZ05PckxK?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Europe approves Genmab's TEPKINLY combo for relapsed follicular lymphoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNQnU3NnNXVm9lM3FhOFF2MUNidnZKaEZQeFBLWUZIQXRvWFp2YnJUNDNMaDgzSDJPb1ljWWw3UDd1a0xjQko4TnRITkNfZTI3dHZ6N2gybGs2SUJIdzFZZ1N4UkN1SlI2Z2JVQVBmd3N4dklJcFdoVEdxWVd6Tms0LUtlRURFY0ZyVTJnM2JuNTRqYklOQS1mYURLUnViV042S202SlBHQkZJRzJnWTd0TEpn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab lymphoma trial cuts progression risk 60% in phase 3 study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNckZUcExPdF92eDZNTC1FamFmaUhwUUFiYTE0OGVxN1FoVFFUMHo4ZEJGS05ZNzFDaTB5RkxnT05lZVplV3BjVWtKVDdHZ3kyMEVNdjJVWWVSSVFhellVR19xRy1TZkd4Q0Q2aktLMThLRGpEYUtjdjdkYkhhUTR4WTRqSTBSempudWxiaWVpbGgzY3BUb3hCYXJ3VE92Ym9ZcDRqWmdQZll1SUhralprczkzeGwwVi1w?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capital Increase in Genmab as a Result of Employee Warrant Exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOZjBhOW9qWTEzaUtGdVotcGZlUDRtVld5QzRFQXFNWHBWZVpUZnh4Q2Y5V3U2U1JEUE5lbjFoa1FRWnJiT3JyWU9qWEVXRzBmUV9qY2kxX21sT3VSY1RKVnEzS2ZablpfODJfN252eGVteFlqQXN1TFRhZlFuNFBpX2s3N2VXYlBpOWNZOVlST2t4QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (NASDAQ: GMAB) issues 185 new shares from employee warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQcFd2MVlaM2k1S0NWcFhRSTBLb2ZLZTdZSVB4bjRIUjVvT3VJUUc0MHpyZGZfRGgyYzRjZmFQMEl4ZTlET3pYM3ZBcXRHT0R1cTJYeDBWX3VkTUZ4Y21IblBFZE5kMlc4NWxsOFRrQ25DVXQ4U282TmF4YldiLUVUVzRQTWRnN3pORldpeXhCTFZ0VXBlWXJnWG1PRFcwOTY1YTNXTEh6SVRiQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Orbis reduces Genmab (GMAB) stake to 4.99% of voting rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUG0yUTFYNVpEcG1lNXFSM1BpTzRjQml3aFhZWktNRDRIemozZ3VWTG1US2luX0dXNXd6Szd3a1E5ZTRoVExoVUtuWHAtenJNSmZHekR4U3E1RTgwb2h3Q3pnYk85Wkx2YzZUR2lJNDBVNWlweWZoblhzQ1gwRTdRLU1WdDV6Qkd5M2pKb0JKT291dExDR2FxNFNMdkN5cUVsdEtDUXlJTVNQZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grant of Restricted Stock Units and Warrants to Employees in Genmab", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOcGl1U3JPOFZkcGxYX2d6dFNlNW1sNmlKUWpjLXhvMDlvdV92N2Q0WTBrbDg3ZUZvZXFNdjB6bHVvbkZ6a0N3V3N0ZEFNc0x6QlJsTVVZdWxoOGFjR0l5Rzl6d2FuX1RkWHlvcDVUbVU1bmNNWHlTRTJJRDdZNUZKTEV5LVMyLTF6RHpYN043LXRBTllRS3pvME9NR3ZqME9IRTFZN0lnSUVIcHU4Q1JzYWpyOWZuOFhCaUJYazZ2S3RLQlNnWkhaMy1XVnptYVhnbEdzYWFB?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Assigns Buy Rating to Genmab (GMAB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNM1VNTnRZb3pWZjUya0VoS2RBdWs1X2VORTgxWlRDTkh1QTdxQWhGOThweHhIaE1lcEdUanFhb3YtbXdnb1ZHLW5ObHQ0bUVUYjZzWnV6VDdNR0x4VWE5VUhQdi1EbF9jZEtuSXFLWHhhS0dOUkpJemlXTE9naFYyWVpRXzBESXNuRE8tcE5uUUR3VlI2d0RQUEhaUWZ6Zw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/ S stock (DK0010272202): board share sale keeps focus on Denmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOdU1KVmlpUUoxUXpPVFQyY2NCMW9rYXEwOHNhMW5hWkF6UDgzbGpVaGdkakdvYkxBNnZXZ1FIdW1QMkpEcEI4ZVVPOHpKd1R2OVpQT0RFTmZUVjBtQUQtOGVqN1QwODUyenhnN1N2RUZCNXdrNm11OGtyczByUTBESEJwcmJDWjJ3TXEwNlZZYTFmLTlzeDR5UHgwUG5iUVl1Rm5XSnp4a0xtc0Nka2lFVGZkVnFoRmtJWC1STk5aX0c3bUNrS0ZB?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab\u2019s epcoritamab phase 3 lymphoma results set for ASCO and EHA 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSEdhWGhwYXZIaDRubmctcF9WdTNQX3FfMjlULWJySy1ZLW9VWVNYX0JsWkRLdm5LUHlROGZ5U3llRktocVhPZ2tKbHpLal9rNFBaZFhHTEh2c29qVXNXX2RsaUIzNkw2R0pydkFGcWxZS1NMZndYOFVuQ2dNX085Y1VKbi1reG9ySEVISGJzMXo2TVVNQTZmMVh0UFZrcXVMQUdNNERVYnF1NE1uUUJCSHhCUUE3WVdBVUFGTw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNLWV6MExvM1NSUEJ5eE5CaU1tZERrby1IaFFnN2IxR2xpWFo0NjVZczY1VUkyT3g4NWI5TU8tMm5iaGVQdU90eEVmMXhoRzhzQnBBd3hSTUdHaTJRSFo3REJHLUpLWjRPSVRPYVNlOFl5SGc5d0VCM1Q2b3JmZ29DOGFla0RManlPdFR4bEVLRnAxbEljNThRdU90aDczdw?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/ S stock (DK0010272202): Shares up 3.48% on employee warrant exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQWHpHWFhUSE85dnVFcTQ3dF9BMjJYbXk5VlhUNm9rZ084YXYzVmdiNk1rLS1ZeHUySFVLbWd1dGZZMXVpd09FV1NabnhnN3hTYk14U0tITXFPak4ycHc1eWkxekhFS2RBQXZmTjhGWFNLTTRidUxqeU9lSjlNODFvektmbDZNUDRxeGZidmNac0FXaXBUV3Bwa1BzN0xuZ3g1WXRVSERINTdwMnJUN0lLeGZNcTBvNWtlamUzRUdQZE8?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi\u2011Year Share Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOUjhiOXlYYkF3RHFBUXVPY2tTbzQ4VlJCandIeDhHMmJrZzl5YWIyVDA2UmRXTTFSLWFlMnNrRnFlcHROUVdZUnVsVHBaSTljOEphVFM2bkhtZWJTbk1fekc2OWVYZnRZLU9VZ3FFT1ZrOVhsNlZxdzFrei1HTWxtdk1lazVfN0xzY0x1Z2ZidWFaNkk4UUdUYUlhNA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNaUh6a2RmMnNjNFB2VnI3MTNTTGlfWTl6WExfRFhzRHRJOHJhdzhYbkNld0NaLUFpekFfemdPbmdSM1pCaG5hcEZTaGQ2WEhZWGJqSXZReWh0djNMZDlrUjZQSWZVbHJaRERwQ0dpRkFBclBZZ29HT1Fvc2VueFFvMG8wR2hMUEZKeDIzZlVaWEhpQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Rated Outperform on Oncology Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZmpxd1NpbTVHX3pZc2VyVjVpWVliSUNWYmFLbmZObkk2ejdmc0k1ME9ZdEwwZjFhVkNIblYyMTJBdWF5NlZfeVVueldkbU9Ydi1EUERPYnVsVUp0cm0wRmZqcXdwOXpZV2tyVXFndWppZHg4a21GN0JQQW9RNzVlUnJpMndkZHJreXNOUEFxZ2VCaHE1ZkhMTDJFT083X1FDMjdneDVvRnBRZw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Genmab\u2019s (CPSE:GMAB) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQOXhrV3ZBMURTTVVITTdQZ1Z3YzYxUE40alV4bEJ1VjN4N19rbTdmdkN1NWVWdThHeXFiOE5WNnotWEFVcE1GVTBIS1dOdzZPNVFWdUxmLUdqM3VCbHdWa09hWGJ5R0JUek9OQnRDZFBISnNfU3NrblpYTGtuTGZKcFFtcXpKaldOT1VMbE9aNHR0WnI3WmVxYjhWd1g?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQk9kRTlPdmQtaF9uUVhlTXhHSjIxd1JJZ2toUEJTUXQ0c3k4N3dqNlNva0VvREJYYWVwaHVNQTBHUm5zbVd6MGZ6OHQya1JPRk5QZ0JvUnhGU21OR1hZNmxQR0FOTDRPTElWUnZ3aThqYXhBdU1aa1ZodVgxWGhMTDRoemtoeFd6TFdnd2hLUi1nN2FFUlpBSkg1ZFVzNVJl?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNdnJwT19rRjVEN3JfUnBWTlJ1bUZZUG1tRWJBX21KYWtDcmJWWkw5MnVOaWgwR0JKeXQwUkU4cU9yOG54R0NiMnoxc1czbjV6eXZyOVV5eHMxb1dtbjExbmUtNXp1UHFocVUwZjFrRHhHYlVDb2xfd3ZNYnVIbGlVczM5aFh6bF82WmJ5eWlpVHdqWHJfa3Z1Vnp2ZDRmRHBaM2RQZ1NNOWRRUzE5QWh3SW8zcFExUDZvRkVKZVRSdVBsZw?oc=5", "source_name": "ChartMill", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNOTZnQTlGYnljWm1NT25BN2tRQVl4dzNqZWIyZU5mOG04MHE1WWJCZTVad2RIaFdXS3l6QUJuTTg0ZjBNWjh0SUNfeU1ZTUtubWtyYWZFZnozWWZjZWxDaWtmQXNYYXdoVWt3UjhIbURYM19CS21FUkZLUl95Tmt1TlljR0dpLW5S?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNcm5lb2IwQUhyVEFlYmFRaG40U0lzUzdOVU5HVzd3ZDFiQk96RHdLWUxVTXcwUGt0MUhCZkloUjQ4akwwUG5WMzZZSGN2N252ajZyMmgyTGp0OExvYlZJby1UQUtFSlhYRUVkQ210YmZkNE8yVXBnQ0RVYnRFMXhMT09R?oc=5", "source_name": "Market source", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB)\u2019s Future Potential Underappreciated by Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOWWlrWWpHU1pOaVU2TlAzaUhtQ19uc3kzU0htYzJyYUJGeTJCRlI3RHRqT21VYzUzYVYxVGhvQVFaWDhtVmtzQktDVUNCS3pjUGxYeFBfbkU4eG1zRnd2X1RKRVhmbTREeFI5NTZ2azFvdW92LTE2dmt1WUpOV3NDRWlNc2M1bWhFYUpwcndmWVhGeWxWOFE?oc=5", "source_name": "Market source", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwJBVV95cUxOSUxlQzR6YUpRV2tWV193V0RHRURoeFNBWjVTWVBmZXduWkpOQ1Z6bGlYX3NlTjB0WEo4eGNWV21jNE9lNlBwc1g0LWRsWTViaEhGUlpzSGh2ZUdnWW5ld1kzSHhQUThPWV9VX1VQekppQ2dBMjNTV3ZlMTBORUR3a1VkUlFhWFhXQ1FEd2JHQ2Y0ZmZfSjJpTjB5endJLVY5czlNQzJwMzY2bkh6VjdmMEFfMTZLTkFFVjFrRnFpckF6TGtESTFiR2hlckpWcTN0VVFyU0RqNUZFNkt2cW9SZkZnWThXN0VsVDhNbmtFVE45YlZJVy1feE52Mk9NUkNLUWZVOFB5ZGZLX25vb3FjWG9VTkdOZktRVjZj?oc=5", "source_name": "Business Wire", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG-Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwJBVV95cUxNbk1fdm9zcGZ4WGRoWW5oLWdpTmV1QkJzdkR2cmtNWm1yamRrM1dUZHExMWJDbGRNTEVES0ZsY1VTbGdmZUkwS0lyOWhkY29XMER0LXBKQmtxaTBVc3BlY1Z4NV9jc05TR1E1Y3QyaUxadjlJdHhfdGNHYkswRFd0ckcyU0xLazVFVXE0M3J4c0kwRl9EemRrSlFfU2VDQk9PTHNrakp3LWtLckdiLUNOYmpqbjFJUDhpTHQ4STFaR3g1OGl1Nm1mZ21RWDFORlY4QThrckJVZWM3dmpTendXaE5fcjRVeE9tcFZZaER5ZFJDYmdPNjRPRnd6THZldUhINlpFRk9QaXNrdEpIR1BRZTlLSXZOUnVFMUFTbnhnTFc5N09YUHFXWGZZUTlCVkU?oc=5", "source_name": "TradingView", "published_at": "2025-04-01T07:00:00+00:00", "published_display": "01 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 81, "total_relevant": 28, "sentiment_summary": {"positive": 7, "negative": 3, "neutral": 18, "score": 54, "total": 28, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1869.0, "latest_week": "2026-07-17", "one_week_move": 0.0, "four_week_move": 14.2, "twelve_week_move": 9.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.767897, "market_dynamics_buy_signal": false, "relative_strength": -5.302872, "fair_value_gap": 2.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.2921, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +14.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 6}, {"label": "ad-hoc-news.de", "count": 5}, {"label": "DirectorsTalk Interviews", "count": 1}, {"label": "GlobeNewswire", "count": 1}, {"label": "Quiver Quantitative", "count": 1}, {"label": "ChartMill", "count": 1}, {"label": "Business Wire", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 28}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 5}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "28", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, +14.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Genmab stock trades mixed as investors weigh Darzalex growth and upcoming earnings"}], "updated_at": "2026-07-18T17:24:32.195580+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}